Implications of PFAS definitions using fluorinated pharmaceuticals.

Implications of PFAS definitions using fluorinated pharmaceuticals.
复制标题

DOI:
10.1016/j.isci.2022.104020
复制
发表时间:
2022-04-15
期刊:
影响因子:
5.8
通讯作者:
Heiger-Bernays W
Heiger-Bernays W
中科院分区:
综合性期刊2区
文献类型:
--
作者:
Hammel E;Webster TF;Gurney R;Heiger-Bernays W

文献摘要

参考文献

被引文献

相似文献

目前存在9000多种全氟烷基和多氟烷基物质,这使得单独研究和管制全氟烷基物质,甚至作为小的混合物是不可行的。已经提出了基于结构的多种全氟辛烷磺酸定义,但这些定义没有考虑到对全套有机氟化学品的影响。例如,有机氟药物,其用途可能是必要的,并在人的血清和废水中发现,但并不是在所有定义中都统一确定。使用不同利益相关者准备的9个定义,我们筛选了1954年至2021年期间全球批准和使用的360种有机氟药物。定义的范围包括有机氟药物(1%-100%)。最具包容性的定义包括几种顶级处方药,例如百忧解和立普妥。这一分析提供了一个框架,组织可以根据该框架来决定如何最好地在定义PFAS时继续进行。对九种PFAS定义进行了评估并用于360种有机氟药物的筛选广泛的定义包括许多顶级处方药物,例如百忧解和立普妥对氟化药物的影响取决于定义的预期用途研究结果有必要讨论制药的可能豁免药学;化学;有机化学;毒理学;全氟烷基物质和多氟烷基物质
There are 9,000+ per- and polyfluoroalkyl substances (PFAS) in existence, which makes studying and regulating PFAS individually, or even as small mixtures, infeasible. Multiple PFAS definitions based on structure have been proposed, yet these definitions do not consider the implications for the full suite of organofluorine chemicals. For example, organofluorine pharmaceuticals, whose use may be essential and are found in human serum and wastewater, are not uniformly identified across all definitions. Using nine definitions prepared by various stakeholders, we screened the 360 organofluorine pharmaceuticals approved and used globally between 1954 and 2021. Definitions ranged in their inclusion of organofluorine pharmaceuticals (1%–100%). The most inclusive definitions include several top prescribed pharmaceuticals, e.g., Prozac and Lipitor. This analysis provides a framework against which organizations can make decisions about how best to proceed when defining PFAS. Nine PFAS definitions were evaluated and used to screen 360 organofluorine drugs Broad definitions include many top prescribed pharmaceuticals, e.g., Prozac and Lipitor Implications for fluorinated pharmaceuticals depend on intended use of the definition Findings necessitate discussion of possible exemptions for pharmaceuticals Pharmaceutical science; Chemistry; Organic chemistry; Toxicology; Per- and polyfluoroalkyl substances
DOI: 10.1289/ehp7431
发表时间: 2021-03
影响因子: 10.4
作者:
Bălan SA;Mathrani VC;Guo DF;Algazi AM
通讯作者: Algazi AM
DOI: 10.1039/d0em00291g
发表时间: 2020-12-01
期刊: Environmental science. Processes & impacts
影响因子: --
作者:
Glüge J ;Scheringer M ;Cousins IT ;DeWitt JC ;Goldenman G ;Herzke D ;Lohmann R ;Ng CA ;Trier X ;Wang Z
通讯作者: Wang Z
DOI: 10.1021/es011055j
发表时间: 2002-03-15
影响因子: 11.4
作者:
Kolpin, DW;Furlong, ET;Buxton, HT
通讯作者: Buxton, HT
DOI: 10.1021/acs.estlett.0c00255
发表时间: 2020-06-30
影响因子: 10.9
作者:
Kwiatkowski CF;Andrews DQ;Birnbaum LS;Bruton TA;DeWitt JC;Knappe DR;Maffini MV;Miller MF;Pelch KE;Reade A;Soehl A;Trier X;Venier M;Wagner CC;Wang Z;Blum A
通讯作者: Blum A
DOI: 10.1021/acs.est.1c03565
发表时间: 2021-07-20
影响因子: 11.4
作者:
Cordner A;Goldenman G;Birnbaum LS;Brown P;Miller MF;Mueller R;Patton S;Salvatore DH;Trasande L
通讯作者: Trasande L